Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of strategies to reduce MRSA infection rates with chlorhexidine and intranasal mupirocin in cardiovascular surgical patients
KCT0005249Phase 4Completed
- Sponsor
- Seoul Pharma Co., Ltd.
- Start
- Dec 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of chlorhexidine, mupirocin in methicillin-resistant Staphylococcus aureus infection (MRSA), sponsored by Seoul Pharma Co., Ltd.. Started Dec 2017; status: completed.
02
Drugs
chlorhexidinemupirocin
03
Conditions
methicillin-resistant Staphylococcus aureus infection (MRSA)
Beyond the preview
Go deeper on KCT0005249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005249.